LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Heron Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.1 -0.9

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.1

Max

1.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-15M

-17M

Pardavimai

1M

38M

Pelnas, tenkantis vienai akcijai

-0.036

Pelno marža

-45.783

Darbuotojai

122

EBITDA

-1.8M

-3.5M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+309.09% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-13M

204M

Ankstesnė atidarymo kaina

2

Ankstesnė uždarymo kaina

1.1

Naujienos nuotaikos

By Acuity

67%

33%

312 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Heron Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-11-14 17:45; UTC

Uždarbis
Pagrindinės rinkos jėgos

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025-11-14 17:31; UTC

Uždarbis
Pagrindinės rinkos jėgos

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025-11-16 23:40; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery -- Market Talk

2025-11-16 23:36; UTC

Rinkos pokalbiai

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

2025-11-16 23:26; UTC

Rinkos pokalbiai

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

2025-11-16 16:20; UTC

Uždarbis

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

2025-11-15 09:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-15 09:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-11-15 00:08; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

2025-11-14 23:56; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025-11-14 23:02; UTC

Rinkos pokalbiai

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025-11-14 22:35; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025-11-14 22:32; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025-11-14 22:29; UTC

Uždarbis

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025-11-14 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025-11-14 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-11-14 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025-11-14 20:27; UTC

Rinkos pokalbiai

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025-11-14 20:23; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025-11-14 20:17; UTC

Įsigijimai, susijungimai, perėmimai

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025-11-14 19:29; UTC

Rinkos pokalbiai
Uždarbis

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025-11-14 18:44; UTC

Rinkos pokalbiai
Uždarbis

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-11-14 18:27; UTC

Rinkos pokalbiai

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025-11-14 18:20; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-11-14 17:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-11-14 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-11-14 16:51; UTC

Rinkos pokalbiai

Starbucks Gets Holiday Sales Lift -- Market Talk

2025-11-14 16:48; UTC

Rinkos pokalbiai

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Akcijų palyginimas

Kainos pokytis

Heron Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

309.09% į viršų

12 mėnesių prognozė

Vidutinis 4.5 USD  309.09%

Aukščiausias 6 USD

Žemiausias 3 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Heron Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

2.0001 / 2.42Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

312 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat